Pentosan Polysulfate vs B7-33.

Pentosan polysulfate sodium (PPS; brand name Elmiron) is a semisynthetic, sulfated polysaccharide derived from beechwood hemicellulose (xylan). It is a low-molecular-weight, heparin-like macromolecule that carries a high density of sulfate groups, giving it weak anticoagulant and broad glycosaminoglycan-mimetic properties. Marketed by Janssen/Ortho, it is the only oral drug approved by the FDA specifically for interstitial cystitis/bladder pain syndrome (IC/BPS).

B7-33 is an experimental single-chain peptide derived from the B-chain of the human hormone relaxin-2 (H2 relaxin). Native relaxin is a complex two-chain molecule linked by disulfide bonds and is difficult and costly to manufacture; B7-33 is a simplified 24-amino-acid single-chain mimetic intended to keep the useful anti-fibrotic activity while being easier to make. It is a laboratory research compound only, studied in cells and animals for fibrosis of the heart, kidney, lung, and blood vessels. It has never been tested in humans and has no approved use. It is categorized under healing because its studied effects are anti-fibrotic and tissue-remodeling.

PPS is thought to act as an exogenous glycosaminoglycan (GAG) that adheres to and replenishes the protective GAG mucus layer lining the bladder urothelium, reducing the permeation of irritating urinary solutes (such as potassium) to underlying nerves and muscle. The FDA label explicitly states the precise mechanism in IC is unknown; proposed contributors include GAG-layer repair, an anti-inflammatory effect, and inhibition of mast cell activity seen in vitro. Its heparin-like structure also gives it mild anticoagulant/fibrinolytic activity and the ability to bind and modulate growth factors and heparanase, which underlies interest in osteoarthritis and antiviral/anti-inflammatory contexts. Oral bioavailability is low (only a few percent is absorbed), with much of the drug eliminated or distributed to connective tissues and the urinary tract.

B7-33 is a functionally selective (biased) agonist of the relaxin family peptide receptor 1 (RXFP1). Rather than strongly activating the cAMP pathway like native relaxin, it preferentially signals through the pERK pathway at RXFP1. This biased signaling is proposed to drive anti-fibrotic effects, notably increased activity of matrix-degrading enzymes such as MMP-2, which break down excess collagen, while potentially avoiding some effects tied to broader relaxin signaling. In preclinical models it has shown vasoprotective and cardioprotective actions consistent with relaxin biology. The single-chain design is meant to preserve receptor engagement without the manufacturing burden of the two-chain hormone.

Human evidence in IC/BPS is genuinely mixed: a meta-analysis and several early randomized trials supported a modest benefit over placebo (roughly 30-40% responders vs 15-20%, a small effect with a high number-needed-to-treat), but the large, well-powered randomized, double-blind trial by Nickel et al. (J Urol, 2015, PMID 25245489) found no significant difference from placebo on its primary endpoint, with response rates near 40% in all arms including placebo. For osteoarthritis, evidence is largely preclinical and early-phase: a small randomized, double-blind, placebo-controlled knee-OA pilot (Ghosh et al., 2005, PMID 24678076) and subsequent phase 2 biomarker/imaging trials (e.g. injectable PPS programs) report signals on pain and cartilage biomarkers, but no large pivotal trial has established disease modification in humans. PPS is investigational and not approved for osteoarthritis, Ross River virus arthralgia, or any veterinary-derived joint indication in humans.

All evidence is preclinical: cell-culture and animal studies, with no clinical trials. B7-33 has never been administered to a human being in a registered study, so no efficacy or safety claim about people can be drawn from the literature that exists. The founding paper (Hossain et al., Chemical Science, 2016) described the design of B7-33 and showed it binds RXFP1 and preferentially activates pERK over cAMP, with anti-fibrotic activity in cell and animal models of heart, lung, and kidney fibrosis. That work combined receptor pharmacology in transfected cell lines with short rodent experiments, using tissue collagen content and enzyme activity as endpoints, in small groups, without the randomization and blinding conventions that govern clinical research. Subsequent work reported vascular and cardiac benefits, including a study finding that B7-33 maintained relaxin's cardioprotective effects and reduced left-ventricular fibrosis more rapidly than the ACE inhibitor perindopril in an experimental model of cardiomyopathy (Alam et al., Biomedicine and Pharmacotherapy, 2023). Additional reports describe effects in myocardial-infarction remodeling and in hypertrophic-scar fibroblasts in vitro. These are early-stage animal and laboratory findings; no human efficacy or safety has been demonstrated, and translation to people is unproven. The cautionary comparison is the parent molecule. Serelaxin, recombinant human relaxin-2, travelled the whole distance: it produced encouraging earlier-phase signals in acute heart failure, then failed to improve clinical outcomes in the large RELAX-AHF-2 trial, and analyses of that dataset have continued to examine why its biomarker and end-organ signals did not convert into patient benefit. A biased RXFP1 agonist that performs well in rodent fibrosis models is therefore starting from a class whose flagship compound already failed a definitive human outcome trial. For B7-33 itself there is no human pharmacokinetic data, no dose-finding work, no formal toxicology package, no immunogenicity assessment, and no registered clinical trial.

The major safety concern that emerged after decades of use is pentosan polysulfate maculopathy, a progressive pigmentary retinal disease first described by Pearce et al. (Ophthalmology, 2018, PMID 29801663) and linked to long-term, high cumulative exposure; it can cause reduced visual acuity and night-vision difficulty (nyctalopia), is often not reversible, and prompted the FDA in June 2020 to add a label warning about retinal pigmentary changes. FAERS pharmacovigilance analyses show a strong disproportionate reporting signal for maculopathy and other retinal disorders in PPS users versus other IC drugs. Because of its heparin-like nature, PPS carries bleeding/anticoagulant risk; other reported effects include reversible alopecia, GI upset, and liver enzyme changes. Much about absolute risk, the exposure threshold for retinal harm, and reversibility after stopping remains uncertain.

There are no human safety data for B7-33 because it has not entered clinical trials; all information comes from cell and animal experiments. Preclinical reports have not flagged prominent toxicities in the models studied, but absence of reported harm in a handful of animal studies is not evidence of human safety. Those studies were small, short, and designed to detect efficacy signals rather than toxicity, and none included the systematic histopathology, reproductive testing, or repeat-administration escalation that regulators require before a first human exposure. Relaxin biology indicates where problems would be looked for. Relaxin is a vasodilator and a systemic tissue-remodeling hormone, so blood pressure effects, renal hemodynamic changes, and unwanted matrix degradation in tissues that were not the target are the plausible concerns for any RXFP1 agonist. The anti-fibrotic mechanism that is desirable in a scarred heart is not obviously desirable everywhere else in the body. Clinical experience with serelaxin showed that an RXFP1 agonist can be given to acutely ill patients without an alarming adverse-event profile, but serelaxin is a different molecule with different signaling bias and different pharmacokinetics, and that experience does not transfer to a single-chain mimetic. Purity, dosing, and long-term effects in humans are entirely unknown, and immunogenicity against a synthetic single-chain sequence has never been assessed. Products marketed online as B7-33 are research chemicals, not medicines, and are not intended for human use, with no verified identity, sterility, or endotoxin testing behind them. This entry is educational only and does not provide any usage guidance.

FDA-approved (since 1996) as Elmiron for the pain/discomfort of interstitial cystitis; in June 2020 the FDA updated its label to warn of retinal pigmentary changes (maculopathy). It is investigational/unproven for osteoarthritis and other inflammatory or antiviral indications.

B7-33 is a preclinical research compound with no FDA or other regulatory approval and no approved indication. It has not been evaluated in human clinical trials. It is sold, where sold, only as a research reagent labeled not for human consumption.